Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New Treatment Option For Managing Anaemia Could Improve Quality Of Life For People With Severe Kidney Disease

The use of an anti-anaemia drug as infrequently as once a month to boost haemoglobin concentrations among people with severe kidney disease could result in improved quality of life and simplified anaemia management compared with conventional therapy for treating anaemia, conclude authors of a study in this week’s issue of The Lancet.

Conventional treatment with epoetin (a synthetic form of human erythropoietin that promotes red-blood cell production) to manage anaemia in chronic kidney disease needs frequent administrations (at least weekly), changes of dose, and close monitoring of haemoglobin concentrations.

Dr Nathan Levin, Renal Research Institute, New York, USA, and colleagues compared the effectiveness of a long-acting erythropoieses-stimulating agent variant of epoetin (methoxy polyethylene glycol-epoetin beta), given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients. The study was designed so that all patients (673 in total, from North America and Europe) received conventional epoetin treatment initially; after four weeks a third of individuals were given methoxy polyethylene glycol-epoetin beta every two weeks, another third given methoxy polyethylene glycol-epoetin beta every four weeks, with the remaining third continuing to receive conventional epoetin treatment throughout the trial..

Haemoglobin concentrations were recorded at baseline, throughout the study, and at a final assessment which took place around a mean of 42 weeks after baseline. The main result of the study showed how individuals given methoxy polyethylene glycol-epoetin beta either fortnightly or every four weeks had no statistically significant change in haemoglobin concentrations compared with those who remained on mainly a three-times-a-week regimen of epoetin treatment throughout the study. Adverse outcomes were minimal and similar between the epoetin and methoxy polyethylene glycol-epoetin beta treatment arms.

Dr Levin comments: “Errors with medication occur at an unacceptably high rate of 45%. Extrapolation to about 246000 haemodialysis patients in the USA suggests that 111000 dose errors could happen every month. Treatment with methoxy poly-ethylene glycol-epoetin beta every 4 weeks would need only 13 doses per year, compared with 52–156 doses with conventional epoetin, and would therefore allow fewer opportunities for error. Since our findings show that haemoglobin can be controlled in all dialysis patients with methoxy polyethylene glycol-epoetin beta given every 4 weeks, we advise that this drug should be introduced as an option to epoetin for simplified anaemia management.”

In an accompanying Comment, Dr Rowan Walker, Royal Melbourne Hospital and Monash University Alfred Hospital, Melbourne, Australia, and Dr Giovanni Strippoli, University of Sydney, Australia, and Mario Negri Sud Consortium, Chieti, Italy, say: “Before we can concur on a precise clinical role for this molecule, we need to explore issues other than simply the non-inferiority with other epoetins to reach certain unvalidated surrogates. Different does and molecular characteristics of epoetins may affect patient-level endpoints, independent of achieved haemoglobin. When these issues are examined, we might be truly confident that a newer molecule is non-inferior to existing ones.”

Tony Kirby | alfa
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>